Viral infection of mammalian cells rapidly triggers intracellular signalling events leading to interferon α/β production and a cellular antiviral state. This ‘host response’ is our first line of immune defence against infection as it imposes several barriers to viral replication and spread. Hepatitis C virus (HCV) evades the host response through a complex combination of processes that include signalling interference, effector modulation and continual viral genetic variation. These evasion strategies support persistent infection and the spread of HCV. Defining the molecular mechanisms by which HCV regulates the host response is of crucial importance and may reveal targets for novel therapeutic strategies.
Subscribe to Journal
Get full journal access for 1 year
only $3.90 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
All prices are NET prices.
Katze, M. G., He, Y. & Gale, M. Jr. Viruses and interferon: a fight for supremacy. Nature Rev. Immunol. 2, 675–687 (2002).
Sen, G. C. Viruses and interferons. Annu. Rev. Microbiol. 55, 255–281 (2001).
Iwasaki, A. & Medzhitov, R. Toll-like receptor control of the adaptive immune responses. Nature Immunol. 5, 987–995 (2004).
Cook, D. N., Pisetsky, D. S. & Schwartz, D. A. Toll-like receptors in the pathogenesis of human disease. Nature Immunol. 5, 975–979 (2004).
McCormick, C. J., Challinor, L., Macdonald, A., Rowlands, D. J. & Harris, M. Introduction of replication-competent hepatitis C virus transcripts using a tetracycline-regulable baculovirus delivery system. J. Gen. Virol. 85, 429–439 (2004).
Sumpter, R. et al. Regulating intracellular anti-viral defense and permissiveness to hepatitis C virus RNA replication through a cellular RNA helicase, RIG-I. J. Virol. 79, 2689–2699 (2005).
Yoneyama, M. et al. The RNA helicase RIG-I has an essential function in double-stranded RNA-induced innate antiviral responses. Nature Immunol. 5, 730–737 (2004).
Li, K., Chen, Z., Kato, N., Gale, M. Jr & Lemon, S. M. Distinct poly-I: C and virus-activated signaling pathways leading to interferon-β production in hepatocytes. J. Biol. Chem. 280, 16739–16747 (2005).
Malmgaard, L. Induction and regulation of IFNs during viral infections. J. Interferon Cytokine Res. 24, 439–454 (2004).
Au, W. C., Moore, P. A., Lowther, W., Juang, Y. T. & Pitha, P. M. Identification of a member of the interferon regulatory factor family that binds to the interferon-stimulated response element and activates expression of interferon-induced genes. Proc. Natl Acad. Sci. USA 92, 11657–11661 (1995).
Lin, R., Heylbroeck, C., Genin, P., Pitha, P. M. & Hiscott, J. Essential role of interferon regulatory factor 3 in direct activation of RANTES chemokine transcription. Mol. Cell. Biol. 19, 959–966 (1999).
Richmond, A. NF-κB chemokine gene transcription and tumour growth. Nature Rev. Immunol. 2, 664–674 (2002).
Barnes, B. J., Moore, P. A. & Pitha, P. M. Virus-specific activation of a novel interferon regulatory factor, IRF-5, results in the induction of distinct interferon alpha genes. J. Biol. Chem. 276, 23382–23390 (2001).
Kawai, T. et al. Interferon-α induction through Toll-like receptors involves a direct interaction of IRF7 with MyD88 and TRAF6. Nature Immunol. 5, 1061–1068 (2004).
Tai, D. I. et al. Activation of nuclear factor κB in hepatitis C virus infection: implications for pathogenesis and hepatocarcinogenesis. Hepatology 31, 656–664 (2000).
Der, S. D., Zhou, A., Williams, B. R. G. & Silverman, R. H. Identification of genes differentially regulated by interferon α, β, or γ using oligonucleotide arrays. Proc. Natl Acad. Sci. USA 95, 15623–15628 (1998).
Wang, C. et al. Alpha interferon induces distinct translational control programs to suppress hepatitis C virus RNA replication. J. Virol. 77, 3898–3912 (2002).
Shimazaki, T., Honda, M., Kaneko, S. & Kobayashi, K. Inhibition of internal ribosomal entry site-directed translation of HCV by recombinant IFN-α correlates with a reduced La protein. Hepatology 35, 199–208 (2002).
Guo, J., Bichko, V. & Seeger, C. Effect of alpha interferon on the hepatitis C virus replication. J. Virol. 75, 8516–8523 (2001).
Prabhu, R. et al. Interferon α-2b inhibits negative-strand RNA and protein expression from full-length HCV1a infectious clone. Exp. Mol. Pathol. 76, 242–252 (2004).
Foy, E. et al. Control of antiviral defenses through hepatitis C virus disruption of retinoic acid-inducible gene-I signaling. Proc. Natl Acad. Sci. USA 102, 2986–2991 (2005).
Smith, M. W. et al. Hepatitis C virus and liver disease: global transcriptional profiling and identification of potential markers. Hepatology 38, 1458–1467 (2003).
Honda, K. et al. IRF-7 is the master regulator of type-I interferon-dependent immune responses. Nature 435, 772–777 (2005).
McHutchison, J. G. & Patel, K. Future therapy of hepatitis C. Hepatology 36, S245–S252 (2002).
Walker, C. M. Comparative features of hepatitis C virus infection in humans and chimpanzees. Springer Semin. Immunopathol. 19, 85–98 (1997).
Bigger, C. B., Brasky, K. M. & Lanford, R. E. DNA microarray analysis of chimpanzee liver during acute resolving hepatitis C virus infection. J. Virol. 75, 7059–7066 (2001).
Su, A. I. et al. Genomic analysis of the host response to hepatitis C virus infection. Proc. Natl Acad. Sci. USA 99, 15669–15674 (2002).
Bigger, C. et al. Intrahepatic gene expression during chronic hepatits C virus infection in chimpanzees. J. Virol. 78, 13779–13792 (2004).
Tuplin, A., Wood, J., Evans, D. J., Patel, A. H. & Simmonds, P. Thermodynamic and phylogenetic prediction of RNA secondary structures in the coding region of hepatitis C virus. RNA 8, 824–841 (2002).
Fredericksen, B. et al. Activation of the inteferon-β promoter during hepatitis C virus RNA replication. Viral Immunol. 15, 29–40 (2001).
Blight, K. J., McKeating, J. A. & Rice, C. M. Highly permissive cell lines for subgenomic and genomic hepatitis C virus RNA replication. J. Virol. 76, 13001–13014 (2002).
Andrejeva, J. et al. The V proteins of paramyxoviruses bind the IFN-inducible RNA helicase, mda-5, and inhibit its activation of the IFN-β promoter. Proc. Natl Acad. Sci. USA 101, 17264–17269 (2004).
Yamamoto, M. et al. Role of adaptor TRIF in the MyD88-independent toll-like receptor signaling pathway. Science 301, 640–643 (2003).
Gong, G., Waris, G., Tanveer, R. & Siddiqui, A. Human hepatitis C virus NS5A protein alters intracellular calcium levels, induces oxidative stress, and activates STAT-3 and NF-κB. Proc. Natl Acad. Sci. USA 98, 9599–9604 (2001).
Sarcar, B., Ghosh, A. K., Steele, R., Ray, R. & Ray, R. B. Hepatitis C virus NS5A mediated STAT3 activation requires co-operation of Jak1 kinase. Virology 322, 51–60 (2004).
Zhu, H. et al. Gene expression associated with interferon α antiviral activity in an HCV replicon cell line. Hepatology 37, 1180–1188 (2003).
Delhem, N. et al. Activation of the interferon-inducible protein kinase PKR by hepatocellular carcinoma derived-hepatitis C virus core protein. Oncogene 20, 5836–5845 (2001).
Williams, B. R. PKR ; a sentinel kinase for cellular stress. Oncogene 18, 6112–6120 (1999).
Tanaka, Y. et al. Selective binding of hepatitis C virus core protein to synthetic oligonucleotides corresponding to the 5′ untranslated region of the viral genome. Virology 270, 229–236 (2000).
Barth, H. et al. Uptake and presentation of hepatitis C virus-like particles by human dendritic cells. Blood 105, 3605–3614 (2005).
Colonna, M., Trinchieri, G. & Liu, Y. J. Plasmacytoid dendritic cells in immunity. Nature Immunol. 5, 1219–1226 (2004).
Li, K. et al. Immune evasion by hepatitis C virus NS3/4A protease-mediated cleavage of the Toll-like receptor 3 adaptor protein TRIF. Proc. Natl Acad. Sci. USA 102, 2992–2997 (2005).
Ferreon, J. C., Ferreon, A. C., Li, K. & Lemon, S. M. Molecular determinants of TRIF proteolysis mediated by the hepatitis C virus NS3/4A protease. J. Biol. Chem. 280, 20483–20492 (2005).
Reed, K. E. & Rice, C. M. in Hepatitis C Virus (ed. Reesink, H. W.) 1–37 (Karger, Basel, 1998).
De Francesco, R. & Steinkuhler, C. Structure and function of the hepatitis C virus NS3–NS4A serine proteinase. Curr. Top. Microbiol. Immunol. 242, 149–169 (2000).
Foy, E. et al. Regulation of interferon regulatory factor-3 by the hepatitis C virus serine protease. Science 300, 1145–1148 (2003).
Sharma, S. et al. Triggering the interferon antiviral response through a novel IKK-related pathway. Science 300, 1148–1151 (2003).
Fitzgerald, K. A. et al. IKKɛ and TBK1 are essential components of the IRF3 signaling pathway. Nature Immunol. 4, 491–496 (2003).
Shoukry, N. H., Cawthon, A. G. & Walker, C. M. Cell-mediated immunity and the outcome of hepatitis C virus infection. Annu. Rev. Microbiol. 58, 391–424 (2004).
Duguay, D. et al. In vivo interferon regulatory factor 3 tumor suppressor activity in B16 melanoma tumors. Cancer Res. 62, 5148–5152 (2002).
Heylbroeck, C. et al. The IRF-3 transcription factor mediates Sendai virus-induced apoptosis. J. Virol. 74, 3781–3792 (2000).
Liang, T. J. & Heller, T. Pathogenesis of hepatitis C-associated hepatocellular carcinoma. Gastroenterology 127, S62–S71 (2004).
Zhu, H. & Liu, C. Interleukin-1 inhibits hepatitis C virus subgenomic RNA replication by activation of extracellular regulated kinase pathway. J. Virol. 77, 5493–5498 (2003).
Heim, M. H., Moradpour, D. & Blum, H. E. Expression of hepatitis C virus proteins inhibits signal transduction through the Jak–STAT pathway. J. Virol. 73, 8469–8475 (1999).
Blindenbacher, A. et al. Expression of hepatitis C virus proteins inhibits interferon α signaling in the liver of transgenic mice. Gastroenterology 124, 1465–1475 (2003).
Duong, F. H., Filipowicz, M., Tripodi, M., La Monica, N. & Heim, M. H. Hepatitis C virus inhibits interferon signaling through up-regulation of protein phosphatase 2A. Gastroenterology 126, 263–277 (2004).
Bode, J. G. et al. IFN-α antagonistic activity of HCV core protein involves induction of suppressor of cytokine signaling-3. FASEB J. 17, 488–490 (2003).
Alexander, W. S. Suppressors of cytokine signalling (SOCS) in the immune system. Nature Rev. Immunol. 2, 410–416 (2002).
Platanias, L. C. & Fish, E. N. Signaling pathways activated by interferons. Exp. Hematol. 27, 1583–1592 (1999).
Macdonald, A. & Harris, M. Hepatitis C virus NS5A: tales of a promiscuous protein. J. Gen. Virol. 85, 2485–2502 (2004).
Geiss, G. K. et al. Gene expression profiling of the cellular transcriptional network regulated by α/β interferon and its partial attenuation by the hepatitis C virus nonstructural 5A protein. J. Virol. 77, 6367–6375 (2003).
Khabar, K. S. et al. The alpha chemokine, interleukin 8, inhibits the antiviral action of interferon α. J. Exp. Med. 186, 1077–1085 (1997).
Polyak, S. J. et al. Hepatitis C virus nonstructural 5A protein induces interleukin-8, leading to partial inhibition of the interferon-induced antiviral response. J. Virol. 75, 6095–6106 (2001).
Polyak, S. J., Khabar, K. S., Rezeiq, M. & Gretch, D. R. Elevated levels of interleukin-8 in serum are associated with hepatitis C virus infection and resistance to interferon therapy. J. Virol. 75, 6209–6211 (2001).
Taylor, D. R., Shi, S. T., Romano, P. R., Barber, G. N. & Lai, M. M. C. Inhibition of the interferon-inducible protein kinase PKR by HCV E2 protein. Science 285, 107–110 (1999).
Noguchi, T. et al. Effects of mutation in hepatitis C virus nonstructural protein 5A on interferon resistance mediated by inhibition of PKR kinase activity in mammalian cells. Microbiol. Immunol. 45, 829–840 (2001).
Gale, M. Jr et al. Control of PKR protein kinase by hepatitis C virus nonstructural 5A protein: molecular mechanisms of kinase regulation. Mol. Cell. Biol. 18, 5208–5218 (1998).
Gimenez-Barcons, M. et al. The oncogenic potential of hepatitis C virus NS5A sequence variants is associated with PKR regulation. J. Interferon Cytokine Res. 25, 152–164 (2005).
Sumpter, R., Wang, C., Foy, E., Loo, Y. -M. & Gale, M. J. Viral evolution and interferon resistance of hepatitis C virus RNA replication in a cell culture model. J. Virol. 78, 11591–11604 (2004).
Taguchi, T. et al. Hepatitis C virus NS5A protein interacts with 2′,5′-oligoadenylate synthetase and inhibits antiviral activity of IFN in an IFN sensitivity-determining region-independent manner. J. Gen. Virol. 85, 959–969 (2004).
Han, J. Q. & Barton, D. J. Activation and evasion of the antiviral 2′,5′ oligoadenylate synthetase/ribonuclease L pathway by hepatitis C virus mRNA. RNA 8, 512–525 (2002).
Han, J. Q., Wroblewski, G., Xu, Z., Silverman, R. H. & Barton, D. J. Sensitivity of hepatitis C virus RNA to the antiviral enzyme ribonuclease L is determined by a subset of efficient cleavage sites. J. Interferon Cytokine Res. 24, 664–676 (2004).
Farci, P. Hepatitis C virus. The importance of viral heterogeneity. Clin. Liver Dis. 5, 895–916 (2001).
Farci, P. et al. Early changes in hepatitis C viral quasispecies during interferon therapy predict the therapeutic outcome. Proc. Natl Acad. Sci. USA 99, 3081–3086 (2002).
Farci, P. et al. The outcome of acute hepatitis C predicted by the evolution of the viral quasispecies. Science 288, 339–344 (2000).
Enomoto, N. et al. Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection. N. Engl. J. Med. 334, 77–81 (1996).
Pascu, M. et al. Sustained virological response in hepatitis C virus type 1b infected patients is predicted by the number of mutations within the NS5A-ISDR: a meta-analysis focused on geographical differences. Gut 53, 1345–1351 (2004).
Schinkel, J., Spoon, W. J. & Kroes, A. C. Meta-analysis of mutations in the NS5A gene and hepatitis C virus resistance to interferon therapy: uniting discordant conclusions. Antivir. Ther. 9, 275–286 (2004).
Blight, K. J., Kolykhalov, A. A. & Rice, C. M. Efficient inititation of HCV RNA replication in cell culture. Science 290, 1972–1974 (2000).
Appel, N., Pietschmann, T. & Bartenschlager, R. Mutational analysis of hepatitis C virus nonstructural protein 5A: potential role of differential phosphorylation in RNA replication and identification of a genetically flexible domain. J. Virol. 79, 3187–3194 (2005).
Mihm, S. et al. Interferon type I gene expression in chronic hepatitis C. Lab. Invest. 84, 1148–1159 (2004).
Fujita, T., Reis, L. F., Watanabe, N., Kimura, Y. & Taniguchi, T. Induction of the transcription factor IRF-1 and interferon-β mRNAs by cytokines and activators of second-messenger pathways. Proc. Natl Acad. Sci. USA 86, 9936–9940 (1986).
Schulz, O. et al. Toll-like receptor 3 promotes cross-priming to virus-infected cells. Nature 433, 887–892 (2005).
Frese, M. et al. Interferon-γ inhibits replication of subgenomic and genomic hepatitis C virus RNAs. Hepatology 35, 694–703 (2002).
McHutchison, J. G. Understanding hepatitis C. Am. J. Manag. Care 10, S21–S29 (2004).
Zhong, J. et al. Robust hepatitis C virus infection in vitro. Proc. Natl. Acad. Sci. USA 102, 9294–9299 (2005).
Lidenbach, B. D. & Rice, C. M. Complete replication of hepatits C virus in cell culture. Science 309, 623–626 (2005).
Wakita, T. et al. Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nature Med. 11, 791–796 (2005).
Pflugheber, J. et al. Regulation of PKR and IRF-1 during hepatitis C virus RNA replication. Proc. Natl Acad. Sci. USA 99, 4650–4655 (2002).
Kanazawa, N. et al. Regulation of hepatitis C virus replication by interferon regulatory factor 1. J. Virol. 78, 9713–9720 (2004).
McWhirter, S. M. et al. IFN-regulatory factor 3-dependent gene expression is defective in Tbk1-deficient mouse embryonic fibroblasts. Proc. Natl Acad. Sci. USA 101, 233–238 (2004).
Yoneyama, M. et al. Direct triggering of the type I interferon system by virus infection: activation of a transcription factor complex containing IRF-3 and CBP/p300. EMBO J. 17, 1087–1095 (1998).
Au, W. C., Yeow, W. S. & Pitha, P. M. Analysis of functional domains of interferon regulatory factor 7 and its association with IRF-3. Virology 280, 273–282 (2001).
Breiman, A. et al. Inhibition of RIG-I-dependent signaling to the interferon pathway during hepatitis C virus expression and restoration of signaling by IKKɛ. J. Virol. 79, 3969–3978 (2005).
We thank S. Lemon and members of our laboratory for discussions and critical evaluation of this manuscript. The Gale laboratory is supported by grants from the NIH, the Ellison Medical Foundation and the Burroughs Wellcome Fund. M.G. is the Nancy C. and Jeffrey A. Marcus Scholar in Medical Research in Honor of Dr Bill S. Vowell.
The authors declare no competing financial interests.
Author Information Reprints and permissions information is available at npg.nature.com/reprintsandpermissions.
About this article
Cite this article
Gale, M., Foy, E. Evasion of intracellular host defence by hepatitis C virus. Nature 436, 939–945 (2005). https://doi.org/10.1038/nature04078
Decreased expression of interferon‐stimulated genes in B cells of patients with chronic hepatitis C during interferon‐free therapy potentially suggests the eradication of hepatitis C virus in the B cells: A cohort study
Health Science Reports (2020)
Cold Spring Harbor Perspectives in Medicine (2020)
The Occurrence of Genetic Recombination between Viruses and Human, it's Possible Influence on Vaccination
Epidemiology and Vaccinal Prevention (2020)
Association of serum levels of C-reactive protein with CRP-717 T/C polymorphism and viremia in HCV and HBV carriers
Revista da Sociedade Brasileira de Medicina Tropical (2019)
Revista da Sociedade Brasileira de Medicina Tropical (2019)